$ACRV News

Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027

Acrivon Therapeutics Advances ACR-7280, Showing Complete Tumor Regression In AML Models, With IND Filing Targeted For H1 2027

What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock

Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

Acrivon Therapeutics Q2 EPS $(0.43) Beats $(0.50) Estimate

Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study

Acrivon Therapeutics Says ACR-2316 Advances Into Randomized Dose Expansion Portion Of Its Ongoing Phase 1/2 Study

Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference

Acrivon Therapeutics To Highlight AP3 Platform For Pathway-Based Drug Discovery And Development At AACR D3 July 21-24

Acrivon Therapeutics: Priced For Failure, Built For Precision

Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts

Acrivon Therapeutics Q1 EPS $(0.49) Beats $(0.53) Estimate

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities

Acrivon Therapeutics Presents Preclinical Data On Three Posters At AACR 2026